Press

In collaboration with the Manke Lab at UMass Dartmouth and the Designer Drug Research Unit at the National Institute on Drug Abuse Intramural Research Program, CaaMTech scientists continue to pioneer new fields of “magic mushroom” research with their latest published academic work, “Synthesis, Structural Characterization, and Pharmacological Activity of Novel Quaternary Salts of 4-Substituted Tryptamines.” Published in the American Chemical Society’s journal, ACS Omega (Structural Chemistry), the multi-disciplinary peer-reviewed research paper builds on the researchers’ previous synthesis, structural characterization, and pharmacological screening of aeruginascin’s active metabolite (4-HO-TMT) and a prospective prodrug thereof (4-AcO-TMT). Psilocybin is the most studied compound in “magic mushrooms.” now the subject of over 100…

Sunstone Therapies, a company dedicated to treating the psychological effects of cancer, announces today the launch of a new clinical trial to test the safety and tolerability of MDMA-assisted therapy for patients living with treatment-resistant post-traumatic stress disorder (PTSD). The trial is sponsored by the Multidisciplinary Association for Psychedelics Studies (MAPS), a non-profit research organization that develops psychedelic medicine. MAPS has received Food and Drug Administration authorization to establish an expanded access program for a limited group of patients who meet the study’s eligibility criteria. “We are grateful to be able to further investigate the potential therapeutic benefits MDMA may…

Psilera Inc., a biopharmaceutical company optimizing next-generation mental health treatments, announces the patent approval of N,N-dimethyltryptamine (DMT) and psilacetin (4-AcO-DMT and psilocybin-like prodrug) transdermal patch formulations. Transdermal application allows patients to dose topically while receiving treatment through the surface of their skin, overcoming the need for intravenous needles and episodic oral dosing. This patient-first approach may solve many of the current industry pitfalls, such as length of treatment time, lack of take-home treatment options, and insurance reimbursement.  “This patent allowance from the U.S. Patent Attorney’s Office marks a flagship milestone for Psilera and the broader mental health industry. We expect several…

ATMA Journey Centers Inc. (“ATMA”), an Alberta-based company focused on the international delivery of innovative psychedelic-assisted therapy solutions, announced today that it has received approval from Health Canada to move forward with its N500 Phase II psilocybin clinical trial. This trial is aimed at studying the potential relief of COVID-19-associated mental health concerns in frontline healthcare providers, as well as documenting healthcare providers’ firsthand evaluation of the potential effectiveness of psilocybin psychotherapy in application. “Health Canada has stated the path forward for psychedelic medicine is through clinical trials. ATMA’s clinical trial platform aims to provide policymakers with the real-world data they require to make…

Mindset Pharma Inc. (CSE: MSET | FSE: 9DF | OTCQB: MSSTF) , a drug discovery company developing novel, optimized, next-generation psychedelic and non-psychedelic medications to treat neuropsychiatric and neurological disorders with unmet medical needs, today announced that the Company has received Scientific Advice from the UK Medicines and Healthcare products Regulatory Agency on a range of points to finalize its Phase 1 first-in-human clinical trial plan evaluating its lead psychedelic drug candidate MSP-1014 for the treatment of Major Depressive Disorders In a meeting with the MHRA, Mindset discussed its plans for Phase 1 first-in-human clinical development of MSP-1014, a novel and…